Study of INCB123667 in Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation and dose-expansion study to determine the safety,
tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered
as monotherapy at the RDE(s) in participants with selected advanced or metastatic solid
tumors. Part 1A (dose escalation) will determine the recommended dose of INCB123667 for
expansion (RDE) and the maximum tolerated dose (MTD). Part 1B (cohort dose expansion phase)
will further explore antitumor activity of INCB123667 as a monotherapy in 4 tumor-specific
cohorts at the RDE(s) defined in Part 1A.